M. Diculescu *, D. Ștefan **, Simona Ozarchevici *, Luminita Neacsu *, Anca Roxana Lupu ***, A. Oproiu *
* Prof. Dr. Alexandru Oproiu, Șef de lucrări Dr. Mircea Diculescu, Dr. Simona Ozarchevici, Student Luminița Neacsu – Centrul de Gastroenterologie Fundeni
** Dr. Dan Ștefan – Beaufour IPSEN International
*** Șef de lucrări Dr. Anca Roxana Lupu – Clinica de Hematologie Spitalul Colțea
Abstract
Irritable bowell syndrome (IBS) is a rather frequent diseasein adults, with a complex pathogenic mechanism and without any organic lesions . Our aim was to test the therapeutical effects of Diosmectite and Loperamide in IBS. Our study was a prospective monocentric study. We had 2 groups of patients: group D had 30 patients with IBS who were treated with diosmectite 9 g/day. Group L had 32 patients and was treated with loperamide 4 mg/ day. Both groups were treated for 30 days and had a definite IBS diagnosis based on clinical data and laboartory exclusion of organic, infective or systemic diseases who could mimick IBS. All 62 patients were evaluated at the beginning, and at days 10, 20, 30. Global efficacy at 30 days was 96.7% with diosmectite and 62.5% with loperamide (number of stools, frequency of abdominal pain, flatulence,borborygme)wich may mean that diosmectite, (antidiarrhoeic and mucoprotective) is better than loperamide in the IBS therapy. These results suggest that usually in IBS smooth muscle hypermotility may be in certain conditions more dependent upon the enterocyte and intraluminal status than upon the nervous system.